Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2021-04-08

Original market date: See footnote 1

2021-04-08

Product name:

PHESGO

Description:

SINGLE USE VIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02512912

Product Monograph/Veterinary Labelling:

Date: 2021-03-01 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

HOFFMANN-LA ROCHE LIMITED
7070 Mississauga Road
Mississauga
Ontario
Canada  L5N 5M8

Class: 

Human

Dosage form(s):

Solution

Route(s) of administration:

Subcutaneous

Number of active ingredient(s):

2

Schedule(s):

Prescription,  Schedule D  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00   ANTINEOPLASTIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01XY  COMBINATIONS OF ANTINEOPLASTIC AGENTS

Active ingredient group (AIG) number:See footnote 5

0254251002

List of active ingredient(s)
Active ingredient(s) Strength
PERTUZUMAB 80 MG / ML
TRASTUZUMAB 40 MG / ML

Application information

Related information

Contact us

Version 3.8.0
Date modified: